Cancer Chemotherapy and Selective Drug Development

Proceedings of the 10th Anniversary Meeting of the Coordinating Committee for Human Tumour Investigations, Brighton, England, October 24–28, 1983

  • Editors
  • K. R. Harrap
  • W. Davis
  • A. H. Calvert

Part of the Developments in Oncology book series (DION, volume 23)

Table of contents

  1. Front Matter
    Pages i-xxv
  2. Advances in Cancer Treatment

    1. Front Matter
      Pages 1-1
    2. New Approaches to Old Problems

      1. J. M. A. Whitehouse
        Pages 5-11
      2. I. E. Smith
        Pages 13-17
      3. R. Powles, G. Goss, A. Pedrazzini, M. Crofts, H. Clink, J. Millar et al.
        Pages 33-41
      4. P. Alexander
        Pages 43-45
    3. Current Clinical Progress with New Agents

      1. S. K. Carter
        Pages 49-53
      2. Colin P. Turnbull, David Jackson
        Pages 55-63
      3. Ann L. Wang, Philip S. Schein
        Pages 71-75
      4. J. L. Toy
        Pages 83-87
    4. Drug Treatment of Specific Cancers

      1. H. H. Hansen
        Pages 91-94
      2. F. Cavalli, A. Goldhirsch, R. Joss, K. W. Brunner
        Pages 95-104
      3. E. Wiltshaw
        Pages 105-109
      4. T. A. Lister, H. S. Dhaliwal
        Pages 117-122
      5. M. G. Mott
        Pages 123-133
      6. Lawrence H. Einhorn
        Pages 135-139
  3. Control of Pain and Vomiting in Cancer Patients

    1. Front Matter
      Pages 145-145
    2. R. G. Twycross
      Pages 147-151
    3. J. Welsh, J. F. B. Stuart, T. Haveshaw, P. Billiaert, K. C. Calman
      Pages 153-158
    4. G. W. Hanks
      Pages 159-163
    5. G. W. Hanks
      Pages 173-176
    6. C. L. Smith
      Pages 177-182
    7. A. L. Harris
      Pages 189-193
  4. Perspectives in New Drug Development

    1. Front Matter
      Pages 205-205
    2. Problems in Achieving Drug Selectivity

      1. A. E. Bogden, J. M. Venditti, W. R. Cobb
        Pages 215-219
      2. G. G. Steel, V. D. Courtenay, R. R. Sandhu
        Pages 221-225
      3. V. L. Narayanan
        Pages 235-239
      4. G. E. Adams, I. J. Stratford, P. W. Sheldon
        Pages 241-247
    3. Targetted Chemotherapy

      1. G. T. Stevenson, V. M. Cole, M. J. Glennie, H. F. Watts
        Pages 257-262
      2. Philip E. Thorpe
        Pages 263-267
    4. Regulatory Molecules in Chemotherapy

      1. R. J. Booth, R. L. Prestidge, J. D. Watson
        Pages 289-293
      2. P. K. Bondy, J. L. Ryan, Z. N. Canellakis
        Pages 295-299
      3. W. A. Boggust, S. O’connell, A. Drumm
        Pages 301-305
  5. Design and Development of New Drugs

    1. Front Matter
      Pages 313-313

About this book


Over the past 30 years many significant advances have been made in the management of a number of disseminated malignant diseases. The prognosis for diseases such as childhood leukaemia, choriocarcinoma and Hodgkin's disease has gradually been transformed as better anti tumour agents have become available and their clinical use has been refined. During the past 10 years the advent of new agents, particularly cisplatin, bleomycin and the podophyllotoxins, has allowed the cure of disseminated testicular tumours. This degree of success has not, however, been achieved in the case of a number of other common cancers. Ovarian carcinoma is tantalisingly chemo-sensitive and although there are long term survivors from disseminated disease, these are only a small proportion of the total. Breast cancer, although "sensitive" to a multitude of drugs appears to have yielded neither survival benefit, nor cure to the efforts of therapists, while tumours such as those of the colon remain stubbornly unresponsive. Against this backcloth it is apparent that additional more selective treatments are needed if further impact is to be made on the problem of cancer. The development of such agents requires the integration of a multidisciplinary effort encompassing the fields of chemistry, biology and medicine. This symposium provided a forum for clinical and preclinical sCientists, where current aspects of cancer treatment were reviewed and approaches to the development of a new generation of more selective anticancer drugs discussed.


cancer treatment carcinoma clinical trial drug design hormones immunotherapy interferon liver lymphocytes lymphoma pain prevention prostate cancer steroids tumor

Bibliographic information